TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2960271
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal therapeutic system
Study: 2960271
Drug: Silver-patch test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver-patch test
Study: 29145543
Drug: Ipilimumab, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab, 10 mg/kg, every 21 days for 4 cycles followed by 4 cycles of maintenance therapy every 12 weeks
Study: 29145543
Drug: Ipilimumab, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab, 3 mg/kg, every 21 days for 4 cycles (run-in safety cohort)
Study: 29145543
Drug: Ipilimumab (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (overall treatment)
Study: 21077506
Drug: 3.9 mg
Normalized name: menthol 3.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.9 mg transdermal 17beta‐estradiol patch
Study: 16004014
Drug: Botox injections
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox injections into one half of the chin
Study: 16004014
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) injections into the other half of the chin
Study: 12857521
Drug: Shen-Fu (SF)
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen-Fu (SF) injection (0.5 ml/kg at the beginning of surgery, followed by continuous infusion of 100 ml SF (1.0 ml/kg) diluted in saline at 0.004 ml x Kg(‐1) x min(‐1))
Study: 12857521
Drug: Shen-Fu (SF)
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen-Fu (SF) injection
Study: 8948561
Drug: Daily screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily screening of respiratory function followed by two-hour trials of spontaneous breathing in appropriate patients.
Study: 8948561
Drug: Daily screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily screening without further intervention (control group).
Study: 2008181
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of pentamidine isethionate every 28 days by inhaler
Study: 2008181
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of sodium isethionate every 28 days by inhaler (placebo)
Study: 20031347
Drug: 5-hydroxytryptophan (5-HTP)
Normalized name: 5-hydroxytryptophan (5-HTP) 50 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptophan (5-HTP) 150 mg/day
Study: 18661495
Drug: Piperacillin-tazobactam (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (125 mg/kg/day) plus ceftazidime (100 mg/kg/day)
Study: 18661495
Drug: Cefozopran (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (100 mg/kg/day)
Study: 15721732
Drug: Promethazine 6.25
Normalized name: DM 15/PROMETHAZINE 6.25MG/5ML SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 6.25 to 25 mg
Study: 15721732
Drug: Dimenhydrinate 25
Normalized name: dimenhydrinate 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate 25 to 50 mg
Study: 15721732
Drug: Droperidol 0.625
Normalized name: droPERidol 0.625 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.625 to 1.25 mg
Study: 10836660
Drug: Ethinylestradiol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol (30 g) and drospirenone (3 mg)
Study: 10836660
Drug: Ethinylestradiol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol (30 g) and desogestrel (150 g)
Study: 9060547
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 plus cisplatin 75 mg/m2
Study: 9060547
Drug: Docetaxel 85
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 85 mg/m2 plus cisplatin 100 mg/m2
Study: 23278775
Drug: Thrice-weekly regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly regimen of antitubercular drugs (2H(3)R(3)Z(3)E(3)/4H(3)R(3)) for 6 months
Study: 10531771
Drug: Buscopan compositum
Normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buscopan compositum (hyoscine butylbromide 20 mg and dipyrone 2.5 g) i.v.
Study: 9004342
Drug: Clonidine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.15 mg)
Study: 2792671
Drug: Acid protection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid protection (antacids, cimetidine, and sucralfate)
Study: 29271052
Drug: Topical hemostatic
Normalized name: ferric sulfate 21 % Topical Hemostatic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hemostatic sealant
Study: 24734241
Drug: lidocaine+lornoxicam+transdermal nitroglycerine
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine+lornoxicam+transdermal nitroglycerine (group LL-N)
Study: 24734241
Drug: lidocaine (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine (group L)
Study: 18322928
Drug: Encouraged to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encouraged to regulate their daily routines
Study: 1965077
Drug: Formalized inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formalized inactivated hepatitis A vaccine (180, 360, and 720 ELISA units)
Study: 1965077
Drug: Formalized inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formalized inactivated hepatitis A vaccine
Study: 382914
Drug: Diazepam (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.4 mg/kg) + Ketamine (2 mg/kg) + Nitrous oxide (50%)
Study: 382914
Drug: Morphine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (3 mg/kg) + Nitrous oxide (50%)
Study: 6847465
Drug: Conjunctival irrigation
Normalized name: Sus scrofa conjunctiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjunctival irrigation with saline solution
Study: 29352714
Drug: Single-agent prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent prednisone
Study: 26544097
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (paclitaxel 200 mg/m² and carboplatin AUC5) and external beam radiotherapy (60 Gy/30 fractions/6 weeks)
Study: 26544097
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (paclitaxel 200 mg/m² and carboplatin AUC5) followed by external beam radiotherapy (48 Gy/20 fractions/4 weeks) with concomitant cisplatin 30 mg/m² weekly
Study: 17626040
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) at a dose of 1 g twice daily
Study: 9618125
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss intervention (6279 kJ/week of physical activity, 33,258-41,462 kJ/week diet and weekly meetings)
Study: 7653978
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 800 mg five times per day for seven days (Group A)
Study: 7653978
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 800 mg five times per day for seven days (Group B)
Study: 7653978
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (both Group A and Group B)
Study: 31999469
Drug: Ultrasound-guided fascia
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided fascia iliaca block with 50 to 60 mL of 0.35% ropivacaine
Study: 31999469
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 20 mL of 0.5% ropivacaine
Study: 27689343
Drug: High-polyphenol orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-polyphenol orange juice (HPJ) (745 mg/L)
Study: 27689343
Drug: Normal-polyphenol orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-polyphenol orange juice (NPJ) (299 mg/L)
Study: 10850521
Drug: Gatifloxacin 200
Normalized name: gatifloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 200 mg (10 mg/ml)
Study: 10850521
Drug: Gatifloxacin 200
Normalized name: gatifloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 200 mg (1 mg/ml)
Study: 10850521
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg (2 mg/ml)
Study: 10850521
Drug: Gatifloxacin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 600 mg (2 mg/ml)
Study: 10850521
Drug: Gatifloxacin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 800 mg (2 mg/ml)
Study: 10850521
Drug: Gatifloxacin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin (all doses)
Study: 8834289
Drug: Current modes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current modes of prophylaxis and treatment for heterotopic ossification
Study: 3911961
Drug: Suprofen 5
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprofen 5 mg/kg
Study: 3911961
Drug: Suprofen 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprofen 7.5 mg/kg
Study: 3911961
Drug: Suprofen 10
Normalized name: suprofen 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprofen 10 mg/kg
Study: 3911961
Drug: Suprofen 1
Normalized name: suprofen 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprofen 1 mg/kg
Study: 3911961
Drug: Suprofen lower
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprofen lower doses (1, 2, 3, 4 mg/kg)
Study: 3911961
Drug: Suprofen (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprofen (all doses)
Study: 26202786
Drug: Sevoflurane-dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane-dexmedetomidine (0.5 μg/kg) (Group SD5, n=24)
Study: 26202786
Drug: Sevoflurane-dexmedetomidine (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane-dexmedetomidine (0.7 μg/kg) (Group SD7, n=25)
Study: 21078194
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (17 acupuncture points used 3 times a week for 4 weeks)
Study: 16634340
Drug: Constraint‐induced therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐induced therapy (mitt on the less affected hand 90% of waking hours for 12 days) with 2‐3 patients per therapist and 6 h of group training per day.
Study: 16634340
Drug: Constraint‐induced group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐induced group therapy.
Study: 12741629
Drug: Combivir (lamivudine
Normalized name: Combivir (lamivudine 150 MG / zidovudine 300 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combivir (lamivudine 150 mg/zidovudine 300 mg twice daily) + abacavir (300 mg twice daily)
Study: 12741629
Drug: Combivir (lamivudine
Normalized name: Combivir (lamivudine 150 MG / zidovudine 300 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combivir (lamivudine 150 mg/zidovudine 300 mg twice daily) + nelfinavir (750 mg every 8 h)
Study: 1457694
Drug: DNA-coated granulated
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA-coated granulated synthetic carbons (30 g, perfusion volume 2.5-3.1 L)
Study: 6725033
Drug: Postural drainage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postural drainage and bronchodilator therapy
Study: 20377490
Drug: Perianal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perianal lidocaine injection
Study: 20377490
Drug: Periprostatic lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periprostatic lidocaine injection
Study: 20377490
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of perianal-intrarectal lidocaine-prilocaine cream
Study: 14609301
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 1200 mg daily (3 times 400 mg) for 120 days
Study: 10513096
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (combined distant and local acupoints)
Study: 3689627
Drug: CGS 14824
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 14824 A (20 mg)
Study: 3689627
Drug: Nicardipine (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (cumulative doses of 1.25, 3.75, and 8.75 mg)
Study: 27466360
Drug: PHE expansion
Normalized name: Phe
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PHE expansion rate (0.31 mL/hour, IQR 0.12-0.55)
Study: 22287402
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg o.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) for 10 days (Group 1, n=60)
Study: 22287402
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg b.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) for 10 days (Group 2, n=50)
Study: 19361602
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (1.5 microg/kg every 20 days for 3 months) plus oral iron
Study: 16638740
Drug: Ritonavir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (200 mg; 4 doses over 2 days)
Study: 11585680
Drug: Subcutaneous IL‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IL‐2 alone (n=13)
Study: 11585680
Drug: Low-dose IFN‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose IFN‐alpha alone (n=5)
Study: 11585680
Drug: High-dose IFN‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN‐alpha alone (n=10)
Study: 31169077
Drug: Cessation pharmacotherapy
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cessation pharmacotherapy
Study: 28719527
Drug: Standard remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard remifentanil administration
Study: 25760354
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion threshold (hemoglobin level <7.5 g per deciliter)
Study: 25760354
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion threshold (hemoglobin level <9 g per deciliter)
Study: 16817839
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg o.d.
Study: 12799312
Drug: Intravenous C-peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous C-peptide
Study: 12799312
Drug: Intravenous C-peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous C-peptide during NOS blockade
Study: 11060747
Drug: Insulin sensitiser
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin sensitiser drugs
Study: 8328549
Drug: Tetracycline hydrochloride
Normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline hydrochloride 1 g/day
Study: 29880175
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg drospirenone/30 μg ethinyl estradiol (OC)
Study: 29880175
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OC and 1700 mg metformin
Study: 26950683
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g transdermal T gel (TT)
Study: 26950683
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral aromatase inhibitor (AI)
Study: 24874317
Drug: Tenoxicam (texamen)
DrugBank: Tenoxicam (DB00469)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (texamen) 20 mg daily for 7 days with therapeutic exercises
Study: 22220822
Drug: Amoxicillin-metronidazole combination
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin-metronidazole combination (500 mg of each, three times a day for 7 days) and One-Stage-Full-Mouth-Disinfection (OSFMD)
Study: 10500075
Drug: UDCA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA plus budesonide (3 mg three times daily)
Study: 8934801
Drug: Astemizole 10
Normalized name: astemizole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 10 mg/day
Study: 1898300
Drug: Aspartame (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (50 mg/kg body weight)
Study: 7129725
Drug: Heating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heating treatment at 45 degrees C
Study: 27858987
Drug: Ruxolitinib 10
Normalized name: ruxolitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 10 mg BID (n=54)
Study: 19281327
Drug: Empirical antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antifungal treatment (amphotericin B deoxycholate 1 mg/kg/day or liposomal amphotericin 3 mg/kg/day)
Study: 19281327
Drug: Preemptive antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive antifungal treatment (amphotericin B deoxycholate 1 mg/kg/day or liposomal amphotericin 3 mg/kg/day)
Study: 19281327
Drug: Preemptive antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive antifungal treatment
Study: 17290726
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (nicotine inhaler and bupropion)
Study: 15318311
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with suspected acute rejection (Group G)
Study: 11771440
Drug: Adjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemoradiation therapy following complete resection of gastric cancer
Study: 11771440
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy following resection of stage III colon cancer
Study: 11771440
Drug: Adjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemoradiation therapy for stages II and III rectal cancer
Study: 11771440
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation therapy for esophageal cancer
Study: 9158353
Drug: Meperidine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (0.6 microgram/ml, 40 mg/h)
Study: 9158353
Drug: Meperidine (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (1.8 micrograms/ml, 120 mg/h)
Study: 3318475
Drug: timolol 0.5%-pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol 0.5%-pilocarpine 2% twice a day
Study: 3318475
Drug: timolol 0.5%-pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol 0.5%-pilocarpine 4% twice a day
Study: 23098680
Drug: Melatonin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (0.5 mg, 2 mg, 6 mg, 12 mg)
Study: 20647477
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) injection with 2,000 microg mouse gp100 DNA
Study: 18704636
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m² on days 1, 8, and 15 of a 28-day cycle
Study: 18704636
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m² (with dose reduction to 800 mg/m² in 5 patients due to toxicity)
Study: 18704636
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m²
Study: 15965168
Drug: Classic laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic laser treatment
Study: 15965168
Drug: Light laser
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light laser treatment
Study: 8916634
Drug: Relapse prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse prevention therapy
Study: 1679254
Drug: Continuous low
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous low dose antipsychotic medication
Study: 1679254
Drug: Intermittent or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent or targeted medication
Study: 1679254
Drug: Established moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established moderate dose antipsychotic medication
Study: 6341252
Drug: Cefroxadine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefroxadine (1 g t.i.d. for five days)
Study: 6341252
Drug: Cephalexin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (1 g t.i.d. for five days)
Study: 31113752
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 250 mg twice daily for 6 months
Study: 24259653
Drug: Doripenem 500
Normalized name: doripenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doripenem 500 mg (1-hour infusion) every 8 hours
Study: 24259653
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g (0.5-hour infusion) every 8 hours
Study: 17986324
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of 20 ml Carbostesin 0.25% at the end of the operation
Study: 17986324
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml placebo (0.9% Saline) injection